CA1186302A - Antagonistes du lrf - Google Patents

Antagonistes du lrf

Info

Publication number: CA1186302A
Authority: CA; Canada
Prior art keywords: phe; accordance; peptide; prepared; chemical equivalent
Prior art date: 1980-04-15
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA000375536A

Other languages

English (en)

Inventor

Wylie W. Vale, Jr.

Jean E.F. Rivier

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Salk Institute for Biological Studies

Original Assignee

Salk Institute for Biological Studies

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1980-04-15

Filing date

1981-04-15

Publication date

1985-04-30

1980-04-15 Priority claimed from US06/140,487 external-priority patent/US4292313A/en

1981-04-15 Application filed by Salk Institute for Biological Studies filed Critical Salk Institute for Biological Studies

1985-04-30 Application granted granted Critical

1985-04-30 Publication of CA1186302A publication Critical patent/CA1186302A/fr

Status Expired legal-status Critical Current

Links

239000005557 antagonist Substances 0.000 title abstract description 6
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 115
150000001413 amino acids Chemical class 0.000 claims abstract description 28
BEBCJVAWIBVWNZ-UHFFFAOYSA-N glycinamide Chemical group NCC(N)=O BEBCJVAWIBVWNZ-UHFFFAOYSA-N 0.000 claims abstract description 17
125000001711 D-phenylalanine group Chemical group [H]N([H])[C@@]([H])(C(=O)[*])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims abstract description 11
HNDVDQJCIGZPNO-RXMQYKEDSA-N D-histidine Chemical group OC(=O)[C@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-RXMQYKEDSA-N 0.000 claims abstract description 10
QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical group C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 claims abstract description 9
COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical group OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 claims abstract description 8
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 7
239000001257 hydrogen Substances 0.000 claims abstract description 7
125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 7
ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical compound OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 claims abstract description 6
125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 claims abstract description 6
125000002252 acyl group Chemical group 0.000 claims abstract description 6
125000004432 carbon atom Chemical group C* 0.000 claims abstract description 4
125000002698 D-tryptophano group Chemical group C(=O)(O)[C@@H](CC1=CNC2=CC=CC=C12)N* 0.000 claims abstract 24
238000000034 method Methods 0.000 claims description 92
-1 acrylyl Chemical group 0.000 claims description 35
229920005989 resin Polymers 0.000 claims description 23
239000011347 resin Substances 0.000 claims description 23
125000006239 protecting group Chemical group 0.000 claims description 20
125000003118 aryl group Chemical group 0.000 claims description 13
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 11
XJODGRWDFZVTKW-LURJTMIESA-N (2s)-4-methyl-2-(methylamino)pentanoic acid Chemical compound CN[C@H](C(O)=O)CC(C)C XJODGRWDFZVTKW-LURJTMIESA-N 0.000 claims description 7
150000001875 compounds Chemical class 0.000 claims description 6
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
238000004519 manufacturing process Methods 0.000 claims description 3
125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
230000001476 alcoholic effect Effects 0.000 claims description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 2
239000000126 substance Substances 0.000 claims 42
231100000252 nontoxic Toxicity 0.000 claims 2
230000003000 nontoxic effect Effects 0.000 claims 2
150000003839 salts Chemical class 0.000 claims 2
102000004196 processed proteins & peptides Human genes 0.000 abstract description 33
230000016087 ovulation Effects 0.000 abstract description 18
206010062767 Hypophysitis Diseases 0.000 abstract description 10
210000003635 pituitary gland Anatomy 0.000 abstract description 10
102000006771 Gonadotropins Human genes 0.000 abstract description 6
108010086677 Gonadotropins Proteins 0.000 abstract description 6
210000002149 gonad Anatomy 0.000 abstract description 6
239000002622 gonadotropin Substances 0.000 abstract description 6
229940094892 gonadotropins Drugs 0.000 abstract description 6
150000003431 steroids Chemical class 0.000 abstract description 6
230000028327 secretion Effects 0.000 abstract description 4
235000013601 eggs Nutrition 0.000 abstract description 2
241000700159 Rattus Species 0.000 description 20
229940024606 amino acid Drugs 0.000 description 15
235000001014 amino acid Nutrition 0.000 description 14
238000012360 testing method Methods 0.000 description 14
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 10
229940088597 hormone Drugs 0.000 description 9
239000005556 hormone Substances 0.000 description 9
238000000338 in vitro Methods 0.000 description 8
238000001727 in vivo Methods 0.000 description 8
238000006467 substitution reaction Methods 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 6
239000000203 mixture Substances 0.000 description 6
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 5
241000124008 Mammalia Species 0.000 description 5
230000008878 coupling Effects 0.000 description 5
238000010168 coupling process Methods 0.000 description 5
238000005859 coupling reaction Methods 0.000 description 5
230000001158 estrous effect Effects 0.000 description 5
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
239000002253 acid Substances 0.000 description 4
125000003277 amino group Chemical group 0.000 description 4
RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 4
230000003042 antagnostic effect Effects 0.000 description 4
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 4
230000037396 body weight Effects 0.000 description 4
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 4
210000003016 hypothalamus Anatomy 0.000 description 4
230000002401 inhibitory effect Effects 0.000 description 4
150000002500 ions Chemical class 0.000 description 4
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 4
230000001817 pituitary effect Effects 0.000 description 4
239000004471 Glycine Substances 0.000 description 3
125000000539 amino acid group Chemical group 0.000 description 3
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
239000002285 corn oil Substances 0.000 description 3
235000005687 corn oil Nutrition 0.000 description 3
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 3
239000000543 intermediate Substances 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
230000004044 response Effects 0.000 description 3
239000007790 solid phase Substances 0.000 description 3
241000894007 species Species 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
229960003604 testosterone Drugs 0.000 description 3
OMGHIGVFLOPEHJ-UHFFFAOYSA-N 2,5-dihydro-1h-pyrrol-1-ium-2-carboxylate Chemical compound OC(=O)C1NCC=C1 OMGHIGVFLOPEHJ-UHFFFAOYSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
125000005076 adamantyloxycarbonyl group Chemical group C12(CC3CC(CC(C1)C3)C2)OC(=O)* 0.000 description 2
238000003556 assay Methods 0.000 description 2
239000003433 contraceptive agent Substances 0.000 description 2
238000010511 deprotection reaction Methods 0.000 description 2
MGHPNCMVUAKAIE-UHFFFAOYSA-N diphenylmethanamine Chemical compound C=1C=CC=CC=1C(N)C1=CC=CC=C1 MGHPNCMVUAKAIE-UHFFFAOYSA-N 0.000 description 2
238000010828 elution Methods 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
239000000186 progesterone Substances 0.000 description 2
229960003387 progesterone Drugs 0.000 description 2
238000003127 radioimmunoassay Methods 0.000 description 2
238000013223 sprague-dawley female rat Methods 0.000 description 2
125000001424 substituent group Chemical group 0.000 description 2
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
OVBICQMTCPFEBS-SATRDZAXSA-N (2s)-1-[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-[bi Chemical compound CC(O)=O.CC(O)=O.C([C@@H](C(=O)N[C@H](CCCCN=C(NCC)NCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 OVBICQMTCPFEBS-SATRDZAXSA-N 0.000 description 1
NSMXQKNUPPXBRG-SECBINFHSA-N (R)-lisofylline Chemical compound O=C1N(CCCC[C@H](O)C)C(=O)N(C)C2=C1N(C)C=N2 NSMXQKNUPPXBRG-SECBINFHSA-N 0.000 description 1
VYMPLPIFKRHAAC-UHFFFAOYSA-N 1,2-ethanedithiol Chemical compound SCCS VYMPLPIFKRHAAC-UHFFFAOYSA-N 0.000 description 1
GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical group OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
101100087530 Caenorhabditis elegans rom-1 gene Proteins 0.000 description 1
VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 1
QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
150000008574 D-amino acids Chemical class 0.000 description 1
ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 description 1
125000003941 D-tryptophan group Chemical group [H]C1=C([H])C([H])=C2C(C([C@@](N([H])[H])(C(=O)[*])[H])([H])[H])=C([H])N([H])C2=C1[H] 0.000 description 1
208000005171 Dysmenorrhea Diseases 0.000 description 1
206010013935 Dysmenorrhoea Diseases 0.000 description 1
201000009273 Endometriosis Diseases 0.000 description 1
JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical group CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 1
241001024304 Mino Species 0.000 description 1
101100305983 Mus musculus Rom1 gene Proteins 0.000 description 1
125000003047 N-acetyl group Chemical group 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
241001610364 Ovula Species 0.000 description 1
102400000050 Oxytocin Human genes 0.000 description 1
XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
101800000989 Oxytocin Proteins 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
LYMVXFSTACVOLP-ZFWWWQNUSA-N Trp-Leu Chemical compound C1=CC=C2C(C[C@H]([NH3+])C(=O)N[C@@H](CC(C)C)C([O-])=O)=CNC2=C1 LYMVXFSTACVOLP-ZFWWWQNUSA-N 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
238000005915 ammonolysis reaction Methods 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
125000002668 chloroacetyl group Chemical group ClCC(=O)* 0.000 description 1
WBLIXGSTEMXDSM-UHFFFAOYSA-N chloromethane Chemical compound Cl[CH2] WBLIXGSTEMXDSM-UHFFFAOYSA-N 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
229940124558 contraceptive agent Drugs 0.000 description 1
230000002254 contraceptive effect Effects 0.000 description 1
125000000753 cycloalkyl group Chemical group 0.000 description 1
229960001305 cysteine hydrochloride Drugs 0.000 description 1
230000007547 defect Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
125000000950 dibromo group Chemical group Br* 0.000 description 1
125000006286 dichlorobenzyl group Chemical group 0.000 description 1
MQYQOVYIJOLTNX-UHFFFAOYSA-N dichloromethane;n,n-dimethylformamide Chemical compound ClCCl.CN(C)C=O MQYQOVYIJOLTNX-UHFFFAOYSA-N 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
150000002148 esters Chemical group 0.000 description 1
230000035558 fertility Effects 0.000 description 1
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
108700032141 ganirelix Proteins 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
230000002710 gonadal effect Effects 0.000 description 1
239000003163 gonadal steroid hormone Substances 0.000 description 1
239000002474 gonadorelin antagonist Substances 0.000 description 1
230000001456 gonadotroph Effects 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
239000000601 hypothalamic hormone Substances 0.000 description 1
229940043650 hypothalamic hormone Drugs 0.000 description 1
JCYWCSGERIELPG-UHFFFAOYSA-N imes Chemical class CC1=CC(C)=CC(C)=C1N1C=CN(C=2C(=CC(C)=CC=2C)C)[C]1 JCYWCSGERIELPG-UHFFFAOYSA-N 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
108010055553 leucyl-arginyl-prolyl-glycinamide Proteins 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
230000035800 maturation Effects 0.000 description 1
230000009826 neoplastic cell growth Effects 0.000 description 1
FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
239000002674 ointment Substances 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
229960001723 oxytocin Drugs 0.000 description 1
238000005192 partition Methods 0.000 description 1
238000004810 partition chromatography Methods 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
125000001557 phthalyl group Chemical group C(=O)(O)C1=C(C(=O)*)C=CC=C1 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229920005990 polystyrene resin Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
208000006155 precocious puberty Diseases 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000008569 process Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
235000018102 proteins Nutrition 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
238000000746 purification Methods 0.000 description 1
239000002516 radical scavenger Substances 0.000 description 1
108700029318 rat female Proteins 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
239000003488 releasing hormone Substances 0.000 description 1
230000007017 scission Effects 0.000 description 1
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
108010080511 serum sodium transport inhibitor Proteins 0.000 description 1
239000008279 sol Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000010532 solid phase synthesis reaction Methods 0.000 description 1
239000000243 solution Substances 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
230000003637 steroidlike Effects 0.000 description 1
210000001550 testis Anatomy 0.000 description 1
125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
WJCNZQLZVWNLKY-UHFFFAOYSA-N thiabendazole Chemical compound S1C=NC(C=2NC3=CC=CC=C3N=2)=C1 WJCNZQLZVWNLKY-UHFFFAOYSA-N 0.000 description 1
125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
PQDJYEQOELDLCP-UHFFFAOYSA-N trimethylsilane Chemical compound C[SiH](C)C PQDJYEQOELDLCP-UHFFFAOYSA-N 0.000 description 1
125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
108010080629 tryptophan-leucine Proteins 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
238000005406 washing Methods 0.000 description 1

Landscapes

Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

CA000375536A 1980-04-15 1981-04-15 Antagonistes du lrf Expired CA1186302A (fr)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US06/140,487 US4292313A (en)	1980-04-15	1980-04-15	LRF Antagonists
US140,487		1980-04-15
US18259480A	1980-08-29	1980-08-29
US182,594		1980-08-29

Publications (1)

Publication Number	Publication Date
CA1186302A true CA1186302A (fr)	1985-04-30

Family

ID=26838224

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000375536A Expired CA1186302A (fr)	1980-04-15	1981-04-15	Antagonistes du lrf

Country Status (3)

Country	Link
CA (1)	CA1186302A (fr)
HU (1)	HU189504B (fr)
PH (1)	PH18518A (fr)

1981
- 1981-04-14 HU HU97781A patent/HU189504B/hu not_active IP Right Cessation
- 1981-04-15 CA CA000375536A patent/CA1186302A/fr not_active Expired
- 1981-04-15 PH PH25510A patent/PH18518A/en unknown

Also Published As

Publication number	Publication date
HU189504B (en)	1986-07-28
PH18518A (en)	1985-08-02

Legal Events

Date	Code	Title	Description
2002-04-30	MKEX	Expiry

Publication	Publication Date	Title
CA1263500A (fr)	1989-11-28	Inhibiteurs de la gnrh ii
US4689396A (en)	1987-08-25	GnRH antagonists V
US4565804A (en)	1986-01-21	GnRH Antagonists VI
NZ500142A (en)	2001-10-26	GnRH antagonists which include modified amino acids at positions 5 and 6
EP0973801A1 (fr)	2000-01-26	ANTAGONISTES DE GnRH
CA1288195C (fr)	1991-08-27	Antagonistes ix des gnrh
IE910380A1 (en)	1991-08-14	CYCLIC GnRH ANTAGONISTS
US4652550A (en)	1987-03-24	GnRH antagonists VII
EP0162575B1 (fr)	1991-09-04	Antagonistes GNRH VII
US4292313A (en)	1981-09-29	LRF Antagonists
EP0063423B1 (fr)	1985-08-14	Antagonistes de GnRH
US4619914A (en)	1986-10-28	GNRH antagonists IIIB
US4740500A (en)	1988-04-26	GnRH antagonists VIII
EP0038135B1 (fr)	1984-07-11	Antagonistes du facteur "LRF"
EP0122712A2 (fr)	1984-10-24	GnRH antagonistes
US4377574A (en)	1983-03-22	Contraceptive treatment of male mammals
CA1186302A (fr)	1985-04-30	Antagonistes du lrf
US4386074A (en)	1983-05-31	LRF Antagonists
US4489061A (en)	1984-12-18	Treatment of male mammals
IE58287B1 (en)	1993-08-25	Spiro-heteroazolones for treatment of diabetes complications
WO1982000004A1 (fr)	1982-01-07	Traitement contraceptif des mammiferes males